---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041606"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:08:07.043724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma Q1 net loss $4.0M; FDA aligned on Phase 3 GTX-104 trial; cash runway to Q2 2025

## Summary
- Net loss $4.0M ($0.54 per share) vs $4.5M ($0.61 per share) year ago.
- Cash and equivalents $21.6M at quarter end; projected runway through Q2 2025 covering potential GTX-104 NDA submission.
- FDA alignment on STRIVE-ON Phase 3 safety trial for GTX-104; first patient dosing expected Q4 2023.
- R&D expenses fell to $1.1M from $2.3M on restructuring; $1.5M severance costs incurred.
- Appointed new CMO, VP Clinical Operations, VP Program Management; expanded Scientific Advisory Board with three key opinion leaders.

## SEC filing metadata
- accession: 0000950170-23-041606
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/0000950170-23-041606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/acst-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041606
- JSON: https://secwatch.observer/filing/0000950170-23-041606.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041606.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported fiscal quarter ended June 30, 2023 results: net income $4.0 million, EPS $0.54 per share.
  - Period: fiscal quarter ended June 30, 2023
  - Net income: $4.0 million
  - EPS: $0.54 per share
  - Result: reported results
  source text: Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023041606/0000950170-23-041606-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.